Compare Newegg Commerce Inc (NEGG) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Newegg Commerce Inc vs TG Therapeutics Inc — how do they compare? Newegg Commerce Inc trades at $19.33 (market cap $414.64M), while TG Therapeutics Inc trades at $48.17 (market cap $7.58B). The key difference: TG Therapeutics Inc is far larger — about 18.3× Newegg Commerce Inc's market cap, and TG Therapeutics Inc is trading nearer its 52-week high, Newegg Commerce Inc nearer its low. Which is the better fit depends on your goals.
| NEGG | TGTX | |
|---|---|---|
Market Cap | $414.64M | $7.58B |
Sector | Consumer Cyclical | Health |
52-Week High | $128.09 | $59.06 |
52-Week Low | $12.87 | $26.94 |
Enterprise Value | $413.44M | $7.78B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Newegg Commerce (NEGG) trades at $19.80, up 7.73% with bullish technical signals and strong recent earnings beats. The stock shows improving fundamentals with revenue stabilizing around $1.4B and net income turning positive in 2026 forecasts. Recent business developments include AI shopping enhancements and exclusive product launches driving growth potential.
Outlook remains cautiously optimistic with improving profitability but carries execution risks. The high P/E ratio of 73.16 suggests premium valuation requiring sustained growth. Key opportunities include technology sector recovery and AI initiatives, while risks involve competitive pressures and cash flow volatility.
TG Therapeutics (TGTX) trades at $49.50, up 0.69% today, with a bearish technical signal from moving averages despite neutral oscillators. The company reported strong revenue growth, with Q2 2026 sales reaching $240 million and raised full-year guidance to $950 million, though it missed earnings estimates for three consecutive quarters. Profitability metrics remain robust with a net income margin of 55.22% and ROE exceeding 100%, but valuation ratios like EV/EBITDA at 56.26 suggest premium pricing.
The outlook is mixed: bullish analyst sentiment with an 84.6% buy rating and a $63.75 price target offers upside potential, driven by Briumvi's commercial success and expansion into schizophrenia trials. However, risks include earnings misses, a shareholder investigation into fiduciary duties, and high cash burn in 2025. Investors should weigh strong revenue momentum against execution risks and elevated valuations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Newegg Commerce Inc
Newegg Commerce Inc is an e-commerce company offering direct sales and an online marketplace platform for IT computer components, consumer electronics, entertainment, smart home and gaming products and provides certain third-party logistics services globally.
Read more on NEGG →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
